H.C. Wainwright Reiterates Buy Rating on MiNK Therapeutics (INKT)

April 23, 2026 7:12 AM

H.C. Wainwright analyst Emily Bodnar reiterated a Buy rating and $35.00 price target on MiNK Therapeutics (NASDAQ: INKT).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found